Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Base Year Market Size (2025) | USD 8.72 Billion |
| Market Size (2026) | USD 9.49 Billion |
| Market Size (2031) | USD 14.51 Billion |
| Growth Rate (2026 - 2031) | 8.85% CAGR |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
North America Cardiac Rhythm Management Devices Market Analysis by Mordor Intelligence
The North America Cardiac Rhythm Management Devices Market size is expected to grow from USD 8.72 billion in 2025 to USD 9.49 billion in 2026 and is forecast to reach USD 14.51 billion by 2031 at 8.85% CAGR over 2026-2031.
A cardiac rhythm management device is an implantable medical device that monitors or regulates the heart's electrical activity to treat various cardiac arrhythmias. These devices are used in several rhythm disorders, such as arrhythmia and other cardiovascular conditions.
Factors such as the surge in the burden of cardiovascular diseases, technological advancements in rhythm management devices, and the rise in the use of ambulatory and home services for cardiac monitoring are anticipated to expedite the market growth during the forecast period.
The increasing prevalence of cardiovascular diseases such as rhythm disorders and atrial fibrillation (AFib) are the major drivers projected to drive the market growth. For instance, according to April 2023 data from the Canadian Cardiovascular Society, atrial fibrillation (AFib) is one of the recurrent types of arrhythmia in clinical practice. It affects around 1% to 2% of the general population, and its risk increases with age.
In addition, according to an article published by the Journal of American Heart Association in April 2024, arrhythmia is a significant comorbidity in the adult congenital heart disease population in the United States. This leads to the high demand for cardiac rhythm management devices such as rhythm management devices, including defibrillators, as they are used to revive patients in an emergency by providing shock. This is anticipated to fuel the industry expansion during the forecast period.
In addition, the launch of awareness campaigns, various programs, and the launch of automated external defibrillator management platforms to promote the importance of fully automated external defibrillators are projected to contribute to the market growth. For instance, in April 2024, Essex-Windsor EMS launched a defibrillator awareness and mapping campaign in Canada. Under this campaign, Essex-Windsor EMS encourages business partners to install automatic defibrillators and promotes their adoption in an emergency.
Similarly, in June 2023, the Lexington Fire Department and the American Heart Association collaborated to launch the LEXSaveLives campaign to promote awareness and education regarding AED (automated external defibrillator) and CPR in the United States. Thus, such awareness and education campaigns are expected to fuel the adoption of rhythm management products in arrhythmia/cardiac arrest, which is anticipated to boost market growth during the forecast period.
The technological advancements in cardiac rhythm management devices, such as the introduction of implantable devices, are expected to drive industry growth in the region. Key players in the industry are undertaking various initiatives to strengthen their business, which will further contribute to the increased adoption of these devices during the forecast period. For instance, in June 2024, Stryker launched a LIFEPAK 35 monitor/defibrillator in the United States to provide life support in emergencies. The newly launched defibrillator is slim, lightweight, and has a portable design. Thus, introducing technologically advanced rhythm management products in North America will likely augment industry uptake during the forecast period.
Therefore, the market is anticipated to grow during the forecast period due to factors such as the high burden of cardiovascular diseases, growing company activities, and rising technological advancements. However, the high cost of devices and stringent regulatory framework about the safety of the products are further expected to impede market growth.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
North America Cardiac Rhythm Management Devices Market Trends and Insights
The Implantable Pacemaker Segment is Expected to Witness Significant Growth During the Forecast Period
A pacemaker is a tiny device that uses electrical impulses implanted in the chest to regulate heartbeat. An implantable pacemaker is a sophisticated medical device designed to regulate and maintain a patient's abnormal heart rhythm by delivering controlled electrical impulses.
The implantable pacemakers (ICPS) segment is expected to witness significant growth in the market amid factors such as the growing burden of cardiovascular diseases (CVDs), technological advancements in implantable pacemakers, and increased demand for the implantable rhythm management system. In addition, several strategic initiatives undertaken by industry participants are further expected to foster segment uptake during the forecast period.
Technological advancements, such as the development of minimally invasive implantable pacemakers with extended battery life and enhanced features, are set to drive their adoption. This, in turn, is projected to fuel growth in the segment during the forecast period. For instance, according to an article published by Science Advances in October 2023, the development of a microtubular implantable pacemaker improved pacing and brought a non-invasive approach to rhythm management. Thus, such technological advancements in implantable pacemakers are likely to foster their adoption, which is anticipated to boost segment uptake over the coming years.
Moreover, the increased uptake of leadless implantable pacemakers across healthcare facilities is another factor projected to spur segment expansion over the coming years. For instance, in March 2024, UC San Diego Health successfully implanted the dual chamber leadless pacemaker to treat irregular heart rhythms. Thus, such an increased uptake of implantable pacemakers across healthcare settings is likely to foster their demand, which is anticipated to boost segment uptake during the forecast period.
Also, several strategic initiatives undertaken by industry participants to accelerate their business avenues are further expected to spur market growth. For instance, in July 2023, Abbott’s dual chamber (DR) leadless pacemaker system, AVEIR, was approved by the United States Food and Drug Administration (US FDA). The newly approved system treats people with abnormal heart rhythms and pacing. Such instances are likely to contribute to the segment expansion.
Therefore, the above-mentioned factors, such as technological advancements in implantable pacemaker technology, growing uptake of pacemaker implants in hospitals, and growing regulatory approvals, are expected to spur segment uptake during the forecast period.
The United States is Expected to Have the Significant Market Share During the Forecast Period
The United States is expected to hold a significant share in the cardiac rhythm management devices market during the forecast period owing to factors such as the high burden of cardiovascular diseases, increasing healthcare expenditure, increasing technological advancements, and growing demand for ambulatory or home services for cardiac monitoring.
The increasing prevalence of cardiovascular diseases is the key factor driving the demand for cardiac rhythm management devices in the country. For instance, according to January 2024 updated data of the American Heart Association, around 605,000 new heart attacks and 200,000 recurrent attacks occur every year in the United States.
In addition, according to the same source, coronary artery diseases, stroke, and heart failure are among the major affecting cardiovascular diseases in the United States. Thus, this profound increase in the burden of cardiovascular diseases in the United States is likely to create a significant demand for rhythm management devices, which, in turn, is anticipated to accelerate market growth during the forecast period.
Moreover, increasing initiatives by public and private organizations to promote awareness regarding cardiovascular diseases and several funding initiatives to accelerate the development of rhythm management products are likely to spur the country’s market growth during the forecast period. For instance, in April 2024, Avive Solutions Inc. raised funding of USD 56.5 million to foster the development of connected AED networks and transform the management of cardiac arrest emergencies. Thus, such funding initiatives are likely to facilitate the development of advanced products, which is expected to boost the country’s market growth during the forecast period.
Also, the increasing company emphasis on the adoption of various key strategies such as new product launches, acquisitions, collaborations, and regulatory approvals are further projected to contribute to the country’s market growth. For instance, in October 2023, the United States Food and Drug Administration (US FDA) approved Medtronic’s extravascular defibrillator to manage irregular heart rhythms and prevent sudden cardiac arrest.
In addition, the increased uptake of rhythm management systems in the United States is further expected to propel market growth. For instance, Hoag Memorial Hospital Presbyterian implanted a dual chamber leadless pacemaker, AVEIR DR of Abbott, in a patient. Such procedures will likely create a sustainable demand for novel products during the forecast period.
Therefore, the market is expected to grow during the forecast period due to the above-mentioned factors, such as the high burden of cardiovascular diseases and growing company activities.
Regulatory Landscape
In North America, cardiac rhythm management devices and adjacent device-drug combination configurations are governed under framework rules that determine the lead center and the applicable quality requirements. In the United States, the FDA assigns primary jurisdiction for combination products based on the Primary Mode of Action (PMOA) under 21 CFR Part 3, while cGMP expectations for combination products are addressed under 21 CFR Part 4 to coordinate device and drug quality system elements.
A key compliance anchor for manufacturers is the FDA Quality Management System Regulation (QMSR), which became effective on February 2, 2026 and incorporates ISO 13485:2016 into the federal quality framework. This affects inspection readiness and quality system alignment for CRM device makers. In Canada, Health Canada manages drug/medical device combination products based on the principal mechanism of action, routing review to either the Medical Devices Regulations or the Food and Food and Drug Regulations, supported by a single-window approach intended to reduce regulatory burden while maintaining oversight across safety and performance.
Competitive Landscape
The North American cardiac rhythm management devices market is consolidated and consists of a few major players. Key players operating in the market are launching advanced products to strengthen their business avenues in the North American market. Some of the key companies in the market include Abbott, Biotronik, Boston Scientific Corporation, Koninklijke Philips NV, Medtronic, SchillerAG, and Shenzhen Mindray Biomedical Electronics Co. Ltd.
North America Cardiac Rhythm Management Devices Industry Leaders
Boston Scientific Corporation
Koninklijke Philips NV
Biotronik
Medtronic
Abbott
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Technology migration toward physiologic pacing creates room for new leads, implant techniques, and follow-up workflows across both hospitals and ambulatory settings. This direction is supported by Medtronic's FDA approval in March 2026 for the OmniaSecure defibrillation lead for placement in the left bundle branch area, aimed at enabling conduction system pacing, alongside continued clinical programs such as a 2026 ClinicalTrials.gov study comparing conduction system pacing with conventional biventricular pacing in heart failure.
A second opportunity set is the expansion of AF therapy ecosystems that connect ablation, stroke-risk mitigation, and rhythm management platforms. At Heart Rhythm Society 2026, Abbott highlighted late-breaking data across its ablation and pacing portfolio, including TactiFlex Duo and early feasibility work around Aveir CSP leadless pacing, while Boston Scientific presented interim real-world evidence on concomitant FARAPULSE PFA and WATCHMAN FLX Pro LAAC procedures. In parallel, the February 2026 FDA transition to QMSR (ISO 13485:2016) increases the value of design controls, supplier quality, and post-market systems, which can favor manufacturers and contract partners that align documentation, audit readiness, and UDI-related processes for complex device configurations.
Recent Industry Developments
- April 2026: Abbott announced late-breaking clinical results at Heart Rhythm Society 2026 across multiple studies, including data tied to its TactiFlex Duo ablation catheter program and its conduction system pacing roadmap. The updates reinforce a portfolio approach that links AF treatment with next-generation pacing, supporting broader hospital adoption pathways beyond single-device selling.
- December 2025: Abbott's Volt Pulsed Field Ablation (PFA) System received US FDA approval to treat atrial fibrillation. The clearance increases competitive intensity in AF therapy and strengthens the procedural ecosystem around electrophysiology workflows that can connect into longer-term rhythm management and monitoring needs.
- April 2024: Essex-Windsor EMS launched a defibrillator awareness and mapping campaign in Canada to encourage installation and visibility of automated external defibrillators among local partners. Increased AED placement and mapping improves bystander access and readiness, supporting higher utilization of external defibrillation solutions and associated service models.
Research Methodology Framework and Report Scope
Market Definition and Coverage
In this study, the market covers revenues generated from cardiac rhythm management devices used to correct or control abnormal heart rhythms across North America, counted at the point of device sale into the healthcare system.
Scope exclusions: We exclude cardiology drug therapy, standalone diagnostic ECG monitoring products, and hospital service revenues that are not part of the device sale.
Segmentation Overview
- Product
- Defibrillators
- Implantable Cardioverter Defibrillators (ICDS)
- External Defibrillators (ED)
- Pacemakers
- Implantable Pacemakers (ICPS)
- External Pacemakers
- Cardiac Resynchronization Therapy Devices
- Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- Cardiac Resynchronization Therapy Pacemakers (CRT-P)
- Defibrillators
- Geography
- United States
- Canada
- Mexico
Data Sources, Market Sizing, and Validation
Desk Research
Desk work starts by mapping procedure and implant context, since device sales move with implant volumes and replacement cycles. For cardiovascular disease indicators, we refer to public sources such as the US Centers for Disease Control and Prevention (CDC), and we use national health statistics agencies in Canada and Mexico for population and aging trends.
We also review US FDA databases for device approvals and safety communications, and CMS coverage and payment signals that can affect adoption timing. For trade and supply-side checks, we use import and export statistics from official customs sources and association publications to understand device flow and pricing direction. Company filings, investor presentations, reputable medical journals, and a paid company financials and intelligence database help us align product mix shifts and major launches with observed market movement. These desk sources are illustrative, and we used additional public references to collect data, clarify assumptions, and validate findings.
Primary Interviews and Surveys
Primary work is used to pressure test the desk assumptions with people who see implant decisions and purchasing in real time. We speak with a mix of clinicians, hospital procurement contacts, distributors, and device-focused industry experts across the United States, Canada, and Mexico, and we use their input to confirm unit trends, replacement behavior, and typical pricing movement by device class.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 33% | CXOs: 17% | |
| Mid tier: 48% | Functional/Unit leaders: 27% | |
| Smaller Players: 19% | Managers: 56% |
Market-Sizing & Forecasting
The core sizing logic uses a top-down approach where procedure and device utilization signals are rebuilt into a revenue pool for North America, then split by device classes based on share indicators gathered in research. To keep the outputs grounded, we corroborate totals with selective bottom-up checks, such as sampled average selling prices multiplied by estimated volumes for pacemakers, ICDs, and CRT implants, and then adjust the final numbers if the ranges do not reconcile.
Key inputs used in the model include implant and replacement mix, aging population share, physician preference shifts toward newer device features, reimbursement and coverage stability, and pricing direction after currency conversion into USD. We also track the pacing of new approvals and safety-related pullbacks because these can change shipment timing within a year. For forecasting, we run scenario analysis around procedure growth and pricing, then align the final path to expert expectations gathered during interviews.
When a variable is not consistently available for Canada or Mexico, we bridge gaps using per-capita procedure proxies and hospital capacity signals, and then re-check the implied device intensity with interview feedback.
Data Validation & Update Cycle
Validation happens in layers, starting with range checks on implied units, pricing, and growth rates, followed by cross-checks against independent signals such as procedure direction, coverage changes, and approval timing. Outliers are reviewed again, and any large variance triggers a targeted re-contact with interviewees so assumptions can be corrected before sign-off.
Before publication, the model and written outputs go through multiple analyst reviews, where inputs, formulas, and the story are checked for internal consistency. Reports are refreshed annually, and interim updates are made if a material event occurs that could change adoption or pricing. Right before delivery, we do a final pass to ensure the latest public updates are reflected in the numbers.
Mordor Intelligence's North America Cardiac Rhythm Management Devices Market Market Size Measured Against Other Published Estimates
Published market values for North America cardiac rhythm management devices can look different across sources because the market boundary is not always treated the same way, and because the build-up variables used for demand and pricing can vary. Differences also show up when one estimate reports an implantable-only view, or when a forecast path is anchored to a more conservative or aggressive procedure outlook.
Procedure and replacement-cycle checks, along with cross-validation against approval timing and reimbursement signals, are the evidence that ties the Mordor Intelligence estimate to the device categories counted in this report, rather than mixing in adjacent monitoring products or broader electrophysiology spend. We also see gaps when external figures apply a single average price across device classes, skip Mexico in practice, or do not clearly state the currency timing used for conversion into USD.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 8.72 B (2025) | |
| Industry Research Publisher A | USD 7.89 B (2024) | Uses a different base year and growth frame, and the disclosed scope is less explicit on how external defibrillators and external pacemakers are treated in the total. |
| Healthcare Analytics Group B | USD 4.82 B (2023) | Restricts scope to implantable CRM devices, which naturally excludes external defibrillators and other non-implantable device revenues counted in broader CRM device totals. |
The spread is mainly explained by scope boundaries and year choices, not a single math difference. When the same geography and device inclusion rules are applied, the remaining variance usually comes from how procedure growth, replacement timing, and pricing progression are updated from year to year.
Key Questions Answered in the Report
How big is the North America Cardiac Rhythm Management Devices Market?
The North America Cardiac Rhythm Management Devices Market size is expected to reach USD 9.49 billion in 2026 and grow at a CAGR of 8.85% to reach USD 14.51 billion by 2031.
What is the current North America Cardiac Rhythm Management Devices Market size?
In 2026, the North America Cardiac Rhythm Management Devices Market size is expected to reach USD 9.49 billion.
Who are the key players in North America Cardiac Rhythm Management Devices Market?
Boston Scientific Corporation, Koninklijke Philips NV, Biotronik, Medtronic and Abbott are the major companies operating in the North America Cardiac Rhythm Management Devices Market.
Which is the fastest growing region in North America Cardiac Rhythm Management Devices Market?
North America is estimated to grow at the highest CAGR over the forecast period (2026-2031).
Which region has the biggest share in North America Cardiac Rhythm Management Devices Market?
In 2025, the North America accounts for the largest market share in North America Cardiac Rhythm Management Devices Market.
What years does this North America Cardiac Rhythm Management Devices Market cover, and what was the market size in 2025?
In 2025, the North America Cardiac Rhythm Management Devices Market size was estimated at USD 9.49 billion. The report covers the North America Cardiac Rhythm Management Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Cardiac Rhythm Management Devices Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
